Advancing Therapies for Neurological Conditions
Pioneering research into the mechanisms of neurodegeneration — from discovery to clinical translation.
Our Approach
We believe breakthrough science starts with understanding the disease, not just the symptoms.
How We Work
How We Advance Science
We begin with rigorous target identification and validation — mapping the molecular pathways underlying neurodegeneration to find the most promising intervention points.
Research Areas
We focus exclusively on neurodegenerative disease — giving our programs depth of scientific expertise and clarity of translational strategy at every stage.
Alzheimer's Disease
Targeting amyloid and tau pathology, neuroinflammation, and synaptic dysfunction to develop disease-modifying therapies for Alzheimer's patients.
Parkinson's Disease
Investigating alpha-synuclein aggregation, mitochondrial dysfunction, and dopaminergic neuron loss to advance neuroprotective treatments.
ALS & Motor Neuron Disease
Exploring RNA metabolism, protein aggregation, and neuroinflammatory mechanisms to develop therapies for ALS and related conditions.
Neuroinflammation
Characterizing microglial and astrocyte biology to identify novel anti-inflammatory targets across multiple neurodegenerative indications.
Drug Discovery Platform
Leveraging high-throughput screening, structural biology, and AI-driven compound design to accelerate the identification of best-in-class candidates.
Biomarkers & Diagnostics
Developing fluid and imaging biomarkers to enable earlier diagnosis, patient stratification, and robust clinical trial endpoints.
Science Built for Patients
Lifex Biolabs Inc was founded on a simple belief: that patients with neurodegenerative disease deserve better therapies — and that rigorous, focused science is the path to delivering them. We work exclusively on neurodegeneration, bringing depth of expertise and urgency of purpose to every program.
From the Lab
Let's Connect
Whether you're a potential partner, investor, or collaborator — we'd love to hear from you.